Arrowhead Pharmaceuticals - Pharma company impresses with strong pipeline!
Reading Time: 1 minute
Business Driver: Arrowhead Pharmaceuticals (ARWR) has focused on the development and commercialization of novel therapies based on RNA interference (RNAi). Among other collaborations, they are working with Novartis (license and development of ARO-SNCA for neurological disorders) and Sarepta Therapeutics (multiple programs, including rare genetic diseases). With REDEMPLO, which has been approved by the FDA for the treatment of familial chylomicronemia syndrome (FCS), they already have an approved product. On December 5th, they treated the first...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
